Asianet Newsable on MSN
Merck scores FDA fast-track review for key cholesterol and cancer drugs with multibillion-dollar potential: report
While one of the drugs reportedly slated for fast-track review is the cholesterol pill Enlicitide Decanoate, the other is Merck's cancer therapy Sacituzumab Tirumotecan.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback